Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Samuel Rabkin, Ph.D.

Co-Author

This page shows the publications co-authored by Samuel Rabkin and Howard Kaufman.
Connection Strength

0.651
  1. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology. 2019; 8(7):1591875.
    View in: PubMed
    Score: 0.202
  2. Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. Oncoimmunology. 2019; 8(4):e1571390.
    View in: PubMed
    Score: 0.200
  3. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci Transl Med. 2018 12 12; 10(471).
    View in: PubMed
    Score: 0.198
  4. Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. J Biol Methods. 2019; 6(2).
    View in: PubMed
    Score: 0.051
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.